RT Journal Article SR Electronic T1 Highly-specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.06.08.21258284 DO 10.1101/2021.06.08.21258284 A1 Eva Piano Mortari A1 Cristina Russo A1 Maria Rosaria Vinci A1 Sara Terreri A1 Ane Fernandez Salinas A1 Livia Piccioni A1 Claudia Alteri A1 Luna Colagrossi A1 Luana Coltella A1 Stefania Ranno A1 Giulia Linardos A1 Marilena Agosta A1 Christian Albano A1 Chiara Agrati A1 Concetta Castilletti A1 Silvia Meschi A1 Paolo Romania A1 Giuseppe Roscilli A1 Emiliano Pavoni A1 Vincenzo Camisa A1 Annapaola Santoro A1 Rita Brugaletta A1 Nicola Magnavita A1 Alessandra Ruggiero A1 Nicola Cotugno A1 Donato Amodio A1 Marta Luisa Ciofi Degli Atti A1 Daniela Giorgio A1 Nicoletta Russo A1 Guglielmo Salvatori A1 Tiziana Corsetti A1 Franco Locatelli A1 Carlo Federico Perno A1 Salvatore Zaffina A1 Rita Carsetti YR 2021 UL http://medrxiv.org/content/early/2021/06/09/2021.06.08.21258284.abstract AB Specific memory B cells and antibodies are reliable read-out of vaccine efficacy. We analyzed these biomarkers after one and two doses of BNT162b2 vaccine. The second dose significantly increases the level of highly-specific memory B cells and antibodies. Two months after the second dose, specific antibody levels decline, but highly specific memory B cells continue to increase thus predicting a sustained protection from COVID-19. Graphical AbstractCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis work was founded by: Italian Ministry of Health RF2013-02358960 grant Italian Ministry of Health COVID-2020-12371817 grant Ricerca Corrente 2021 5 per mille Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval was obtained from the Ethics Committee at OPBG, Bambino Gesu Children Hospital. According to the guidelines on Italian observational studies as established by the Italian legislation about the obligatory occupational surveillance and privacy management; Health Care Wokers (HCWs) confidentiality was safeguarded, and informed consent was obtained from all the participants. The study was performed in accordance with the Good Clinical Practice guidelines, the International Conference on Harmonization guidelines, and the most recent version of the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available in the main text or the supplementary materials.